The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2011Validation of Lysosomal Enzymes Assay in CSF - One-year Extension of the RRIA: CSF Lysosomal Hydrolases' Activity as Possible Marker of Parkinson's Disease
Promising Outcomes of Original Grant:
To date, there is no accepted diagnostic test based on biochemical analysis of blood or cerebrospinal fluid (CSF) for clinical diagnosis of PD. Recent studies... -
Biomarkers, 2011Development of an MRI-based Imaging Biomarker for the Detection of Alpha-Synuclein in Parkinson's disease
Objective/Rationale:
Parkinson’s disease is associated with accumulation of the protein α-synuclein in the brain, however, it is not currently possible to detect α-synuclein in the brain of Parkinson... -
Target Validation, 2011Preferential Targeting of Subpopulations of 5-HT1A Receptors
Objective/Rationale:
Although Parkinson's disease (PD) is primarily caused by dopamine dysfunction, function of serotonin (another neurotransmitter) is also affected. This suggests that serotonergic... -
LRRK2, 2011Neuropathological tissue collection in LRRK2 Mutant carriers with and without PD
Objective/Rationale:
Neuropathological studies have been vital in Parkinson’s disease (PD) research. The gold-standard diagnosis of PD is confirmed at autopsy. In addition, information on key proteins... -
MJFF Research Grant, 2011Generation of LRRK2 Lentiviral Vectors
Objective/Rationale:
Overexpression of LRRK2 in mammalian cells, either transient or as stable cell lines, has proven cumbersome and quite inefficient. This can be partly attributed to the large size... -
Research Grant, 2011LRRK2 Effects on Neural Differentiation (Supplement 1)
Promising Outcomes of Original Grant:
Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) account for up to 13% of familial Parkinson's disease (PD) patients. One widely held...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.